4CPS-077 Clinical-epidemiological characteristics of a cohort of patients treated with doravirine

Background and ImportanceDoravirine is a non-competitive, non-nucleoside reverse transcriptase inhibitor (RTI), used in combination regimens with other antiretrovirals for the treatment of HIV-1 without evidence of resistance to non-nucleoside inhibitors.Aim and ObjectivesTo describe the clinical-epidemiological characteristics and the clinical and analytical evolution of DORA associated with (ABC/3TC), (DTG) and (RPV).Material and MethodsTo assess the efficacy of DORA, clinical response was analysed through follow-up consultations and serological tests, measuring viral load (VL), CD4-T lymphocytes, liver profile, and renal function. Follow-up was performed at 2, 4 and 6 months from the start of treatment.ResultsWe followed up 36 patients (31 men), with a mean age of 53.8 years (26-64), 20 were being treated with (ABC/3TC+DORA), 9 with (RPV+DORA) and 7(DTG+DORA). 77% were smokers and 7 of them diagnosed with alcohol habit. At the beginning, 94.4% had undetectable viral load (VL10x6 cop/ml, probably due to non-compliance or abandonment of treatment. VL